Single in-body CAR T injection produced clinical improvements in a small MS trial

# What happened A small clinical trial tested an alternative approach to CAR T therapy: instead of removing a patient's T cells, engineering them in a lab, and reinfusing them, researchers gave a single injection of a virus carrying genetic instructions to turn T cells in the body into CAR T cells. Sixteen people with multiple sclerosis and other neurologic autoimmune disorders received the shot. Over follow-up, symptoms and molecular markers improved for more than six months and there were few severe side effects.

Traditional CAR T requires harvesting a patient's T cells, engineering them in a specialized facility, and returning them to the patient. That process can take weeks, costs hundreds of thousands of dollars, and typically requires preconditioning chemotherapy to make room for the new cells.

This trial used in vivo delivery: a viral vector carrying the gene for a chimeric antigen receptor (CAR) was injected directly into patients. The vector reprogrammed T cells inside the body, in principle making CAR T therapy faster, cheaper, and more like a conventional drug because the same formulation could be used across patients.

# What the results showed

• Clinical signals: Across three different neurologic autoimmune diseases, participants showed symptom improvements lasting at least six months. The article describes this as an immune "reset" with restoration of parts of the immune system toward normal.
• Safety: The trial reported few severe side effects and manageable adverse events in the 16 volunteers. The authors described the results as proof-of-concept that in vivo CAR T generation can be associated with manageable side effects and potential effectiveness for refractory neurologic autoimmune disorders.

# Safety questions and risks

• Off-target delivery: Delivering genetic cargo inside the body reduces control over which cell types receive the CAR gene. If non-T cells are transduced, unintended effects could occur.
• Genomic integration: A delivered gene could integrate into host DNA and theoretically contribute to oncogenic mutations.

# Why this matters now In vivo CAR T could simplify production, remove the need for individualized cell manufacturing, reduce cost and time to treatment, and avoid chemotherapy used to clear room for infused CAR T cells. If larger trials confirm safety and efficacy, the approach could broaden access beyond current logistical and cost constraints.

# Limitations and next steps

# Bottom line A single injection that reprograms T cells in the body produced encouraging short-term clinical and molecular improvements in 16 people with neurologic autoimmune disease and had few severe adverse events. The approach could simplify CAR T delivery, but unresolved safety issues and the small, uncontrolled nature of this trial mean larger, controlled studies are needed before clinical use.